{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:47:32Z","timestamp":1793119652315,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS003130"],"award-info":[{"award-number":["NS003130"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s13311-022-01265-0","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T18:04:56Z","timestamp":1657735496000},"page":"1313-1328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Fluconazole Is Neuroprotective via Interactions with the IGF-1 Receptor"],"prefix":"10.1016","volume":"19","author":[{"given":"Valerie","family":"Toodle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myoung-Hwa","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzna","family":"Bachani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Ruffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Vivekanandhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasir","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongguang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tory P.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0927-5855","authenticated-orcid":false,"given":"Avindra","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-022-01265-0_bib1","doi-asserted-by":"crossref","unstructured":"Group GBDNDC. Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16(11):877\u201397.","DOI":"10.1016\/S1474-4422(17)30299-5"},{"issue":"5","key":"10.1007\/s13311-022-01265-0_bib2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Collaborators","year":"2019","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1007\/s13311-022-01265-0_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","article-title":"Forecasting the global burden of Alzheimer's disease","volume":"3","author":"Brookmeyer","year":"2007","journal-title":"Alzheimers Dement"},{"issue":"11\u201312","key":"10.1007\/s13311-022-01265-0_bib4","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1089\/ars.2006.8.2089","article-title":"Oxidative stress and therapeutic approaches in HIV dementia","volume":"8","author":"Steiner","year":"2006","journal-title":"Antioxid Redox Signal"},{"key":"10.1007\/s13311-022-01265-0_bib5","unstructured":"How is Alzheimer's disease treated? : National Institute on Aging; 2021 [updated July 8, 2021. Available from: https:\/\/www.nia.nih.gov\/health\/how-alzheimers-disease-treated."},{"key":"10.1007\/s13311-022-01265-0_bib6","doi-asserted-by":"crossref","unstructured":"Mukhopadhyay S, Banerjee D. A primer on the evolution of aducanumab: the first antibody approved for treatment of Alzheimer's disease. J Alzheimers Dis. 2021.","DOI":"10.3233\/JAD-215065"},{"issue":"1","key":"10.1007\/s13311-022-01265-0_bib7","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1212\/WNL.0000000000008699","article-title":"Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease","volume":"94","author":"Feustel","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1007\/s13311-022-01265-0_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1007\/s13311-022-01265-0_bib9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1021\/bp049804z","article-title":"Selective isolation and purification of tat protein via affinity membrane separation","volume":"21","author":"Hollman","year":"2005","journal-title":"Biotechnol Prog"},{"issue":"3","key":"10.1007\/s13311-022-01265-0_bib10","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1128\/jvi.71.3.2495-2499.1997","article-title":"Molecular determinants for cellular uptake of Tat protein of human immunodeficiency virus type 1 in brain cells","volume":"71","author":"Ma","year":"1997","journal-title":"J Virol"},{"issue":"3","key":"10.1007\/s13311-022-01265-0_bib11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ana.410370314","article-title":"Human immunodeficiency virus type 1 tat activates non-N-methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity","volume":"37","author":"Magnuson","year":"1995","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1007\/s13311-022-01265-0_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081720","article-title":"Derivation of neural stem cells from human adult peripheral CD34+ cells for an autologous model of neuroinflammation","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS ONE"},{"issue":"1\u20132","key":"10.1007\/s13311-022-01265-0_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J Immunol Methods"},{"issue":"5","key":"10.1007\/s13311-022-01265-0_bib14","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s13365-013-0194-6","article-title":"Impaired neurogenesis and neurite outgrowth in an HIV-gp120 transgenic model is reversed by exercise via BDNF production and Cdk5 regulation","volume":"19","author":"Lee","year":"2013","journal-title":"J Neurovirol"},{"issue":"6459","key":"10.1007\/s13311-022-01265-0_bib15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/367188a0","article-title":"Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice","volume":"367","author":"Toggas","year":"1994","journal-title":"Nature"},{"key":"10.1007\/s13311-022-01265-0_bib16","doi-asserted-by":"crossref","unstructured":"Li W, Lee MH, Henderson L, Tyagi R, Bachani M, Steiner J, Campanac E, Hoffman DA, von Geldern G, Johnson K, Maric D, Morris HD, Lentz M, Pak K, Mammen A, Ostrow L, Rothstein J, Nath A. Human endogenous retrovirus-K contributes to motor neuron disease. Sci Transl Med. 2015 Sep 30;7(307):307ra153. https:\/\/doi.org\/10.1126\/scitranslmed.aac8201.","DOI":"10.1126\/scitranslmed.aac8201"},{"issue":"6","key":"10.1007\/s13311-022-01265-0_bib17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s13365-012-0122-1","article-title":"Catechins protect neurons against mitochondrial toxins and HIV proteins via activation of the BDNF pathway","volume":"18","author":"Nath","year":"2012","journal-title":"J Neurovirol"},{"issue":"1","key":"10.1007\/s13311-022-01265-0_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0301-0082(97)00053-1","article-title":"Neurobiological aspects of human immunodeficiency virus infection: neurotoxic mechanisms","volume":"54","author":"Nath","year":"1998","journal-title":"Prog Neurobiol"},{"issue":"6","key":"10.1007\/s13311-022-01265-0_bib19","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ana.410190603","article-title":"The AIDS dementia complex: II","volume":"19","author":"Navia","year":"1986","journal-title":"Neuropathology Ann Neurol"},{"issue":"6","key":"10.1007\/s13311-022-01265-0_bib20","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","article-title":"Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients","volume":"45","author":"Bellmann","year":"2017","journal-title":"Infection"},{"key":"10.1007\/s13311-022-01265-0_bib21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.nbd.2017.04.010","article-title":"Regulation of motor proteins, axonal transport deficits and adult-onset neurodegenerative diseases","volume":"105","author":"Brady","year":"2017","journal-title":"Neurobiol Dis"},{"issue":"16","key":"10.1007\/s13311-022-01265-0_bib22","doi-asserted-by":"crossref","first-page":"12864","DOI":"10.1074\/jbc.M001492200","article-title":"Cyclic AMP inhibits Akt activity by blocking the membrane localization of PDK1","volume":"276","author":"Kim","year":"2001","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1007\/s13311-022-01265-0_bib23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB signaling: navigating the network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"issue":"12","key":"10.1007\/s13311-022-01265-0_bib24","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1745-7270.2008.00483.x","article-title":"DNA microarray analysis of fluconazole resistance in a laboratory Candida albicans strain","volume":"40","author":"Yan","year":"2008","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"5","key":"10.1007\/s13311-022-01265-0_bib25","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1128\/AAC.28.5.648","article-title":"Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans","volume":"28","author":"Humphrey","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1007\/s13311-022-01265-0_bib26","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/infdis\/157.1.178","article-title":"Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system","volume":"157","author":"Arndt","year":"1988","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1007\/s13311-022-01265-0_bib27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2165\/00003088-199733010-00005","article-title":"Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses","volume":"33","author":"Debruyne","year":"1997","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1007\/s13311-022-01265-0_bib28","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1128\/AAC.44.6.1743-1744.2000","article-title":"Cyclic AMP and fluconazole resistance in Saccharomyces cerevisiae","volume":"44","author":"Kontoyiannis","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s13311-022-01265-0_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.559975","article-title":"Mitochondrial Complex I Core Protein Regulates cAMP Signaling via Phosphodiesterase Pde2 and NAD Homeostasis in Candida albicans","volume":"11","author":"She","year":"2020","journal-title":"Front Microbiol"},{"issue":"4","key":"10.1007\/s13311-022-01265-0_bib30","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/BF00501483","article-title":"Effect of catecholamines, histamine and oxyfedrine on isotonic contraction and cyclic AMP in the guinea-pig heart","volume":"278","author":"Kukovetz","year":"1973","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1007\/s13311-022-01265-0_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-642-17969-3_1","article-title":"Phosphodiesterase inhibitors: history of pharmacology","volume":"204","author":"Schudt","year":"2011","journal-title":"Handb Exp Pharmacol"},{"issue":"3","key":"10.1007\/s13311-022-01265-0_bib32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1083\/jcb.151.3.483","article-title":"Akt regulates cell survival and apoptosis at a postmitochondrial level","volume":"151","author":"Zhou","year":"2000","journal-title":"J Cell Biol"},{"issue":"4","key":"10.1007\/s13311-022-01265-0_bib33","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0092-8674(00)81883-8","article-title":"PI3K: downstream AKTion blocks apoptosis","volume":"88","author":"Franke","year":"1997","journal-title":"Cell"},{"key":"10.1007\/s13311-022-01265-0_bib34","unstructured":"Siegel GJ. Basic neurochemistry : molecular, cellular, and medical aspects. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 1999. xxi, 1183 p."},{"issue":"5","key":"10.1007\/s13311-022-01265-0_bib35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.7150\/ijms.5.240","article-title":"IGF-1 regulates cAMP levels in astrocytes through a beta2-adrenergic receptor-dependant mechanism","volume":"5","author":"Chesik","year":"2008","journal-title":"Int J Med Sci"},{"issue":"46","key":"10.1007\/s13311-022-01265-0_bib36","doi-asserted-by":"crossref","first-page":"29347","DOI":"10.1074\/jbc.271.46.29347","article-title":"Insulin-like growth factor receptor-1 stimulates phosphorylation of the beta2-adrenergic receptor in vivo on sites distinct from those phosphorylated in response to insulin","volume":"271","author":"Karoor","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-022-01265-0_bib37","doi-asserted-by":"crossref","unstructured":"Hadcock JR, Port JD, Gelman MS, Malbon CC. Cross-talk between tyrosine kinase and G-protein-linked receptors. Phosphorylation of beta 2-adrenergic receptors in response to insulin. J Biol Chem. 1992;267(36):26017\u201322.","DOI":"10.1016\/S0021-9258(18)35710-7"},{"key":"10.1007\/s13311-022-01265-0_bib38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1471-2202-7-51","article-title":"Insulin-like growth factor-1 (IGF-1) induces the activation\/phosphorylation of Akt kinase and cAMP response element-binding protein (CREB) by activating different signaling pathways in PC12 cells","volume":"7","author":"Zheng","year":"2006","journal-title":"BMC Neurosci"},{"issue":"3","key":"10.1007\/s13311-022-01265-0_bib39","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1128\/MCB.17.3.1595","article-title":"Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt","volume":"17","author":"Kulik","year":"1997","journal-title":"Mol Cell Biol"},{"key":"10.1007\/s13311-022-01265-0_bib40","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fncel.2019.00298","article-title":"Astrocytic Insulin-Like Growth Factor-1 Protects Neurons Against Excitotoxicity","volume":"13","author":"Chen","year":"2019","journal-title":"Front Cell Neurosci"},{"issue":"13","key":"10.1007\/s13311-022-01265-0_bib41","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1089\/neu.2017.5374","article-title":"Central Infusion of Insulin-Like Growth Factor-1 Increases Hippocampal Neurogenesis and Improves Neurobehavioral Function after Traumatic Brain Injury","volume":"35","author":"Carlson","year":"2018","journal-title":"J Neurotrauma"},{"key":"10.1007\/s13311-022-01265-0_bib42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fnins.2016.00052","article-title":"IGF-I: a key growth factor that regulates neurogenesis and synaptogenesis from embryonic to adult stages of the brain","volume":"10","author":"Nieto-Estevez","year":"2016","journal-title":"Front Neurosci"},{"issue":"5","key":"10.1007\/s13311-022-01265-0_bib43","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1460-9568.2009.06870.x","article-title":"IGF-I promotes neuronal migration and positioning in the olfactory bulb and the exit of neuroblasts from the subventricular zone","volume":"30","author":"Hurtado-Chong","year":"2009","journal-title":"Eur J Neurosci"},{"issue":"4","key":"10.1007\/s13311-022-01265-0_bib44","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrn3209","article-title":"The many faces of insulin-like peptide signalling in the brain","volume":"13","author":"Fernandez","year":"2012","journal-title":"Nat Rev Neurosci"},{"issue":"7","key":"10.1007\/s13311-022-01265-0_bib45","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1210\/er.2004-0024","article-title":"The insulin-like growth factor system and its pleiotropic functions in brain","volume":"26","author":"Russo","year":"2005","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1007\/s13311-022-01265-0_bib46","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1210\/endo.138.4.5092","article-title":"Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins","volume":"138","author":"Parrizas","year":"1997","journal-title":"Endocrinology"},{"issue":"3","key":"10.1007\/s13311-022-01265-0_bib47","first-page":"553","article-title":"Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency","volume":"5","author":"Fintini","year":"2009","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"10.1007\/s13311-022-01265-0_bib48","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archneurol.2010.227","article-title":"Open-label trial of recombinant human insulin-like growth factor 1\/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1","volume":"68","author":"Heatwole","year":"2011","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1007\/s13311-022-01265-0_bib49","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/mus.26846","article-title":"Recombinant human insulin-like growth factor-1 therapy for 6 months improves growth but not motor function in boys with Duchenne muscular dystrophy","volume":"61","author":"Rutter","year":"2020","journal-title":"Muscle Nerve"},{"issue":"22","key":"10.1007\/s13311-022-01265-0_bib50","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1212\/01.wnl.0000335970.78664.36","article-title":"Subcutaneous IGF-1 is not beneficial in 2-year ALS trial","volume":"71","author":"Sorenson","year":"2008","journal-title":"Neurology"},{"issue":"6","key":"10.1007\/s13311-022-01265-0_bib51","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s13365-014-0283-1","article-title":"Combination fluconazole\/paroxetine treatment is neuroprotective despite ongoing neuroinflammation and viral replication in an SIV model of HIV neurological disease","volume":"20","author":"Meulendyke","year":"2014","journal-title":"J Neurovirol"},{"issue":"1","key":"10.1007\/s13311-022-01265-0_bib52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s13365-017-0587-z","article-title":"Paroxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trial","volume":"24","author":"Sacktor","year":"2018","journal-title":"J Neurovirol"},{"issue":"7","key":"10.1007\/s13311-022-01265-0_bib53","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2174\/1389200215666141125121511","article-title":"Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450","volume":"15","author":"Niwa","year":"2014","journal-title":"Curr Drug Metab"},{"issue":"1","key":"10.1007\/s13311-022-01265-0_bib54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.toxlet.2005.11.015","article-title":"Fluconazole-induced hepatic cytochrome P450 gene expression and enzymatic activities in rats and mice","volume":"164","author":"Sun","year":"2006","journal-title":"Toxicol Lett"},{"issue":"9","key":"10.1007\/s13311-022-01265-0_bib55","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1248\/bpb.28.1805","article-title":"Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes","volume":"28","author":"Niwa","year":"2005","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"10.1007\/s13311-022-01265-0_bib56","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1007\/s13311-022-01265-0_bib57","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1517\/17425255.3.4.583","article-title":"The role of cytochrome P450 in antiretroviral drug interactions","volume":"3","author":"Walubo","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1007\/s13311-022-01265-0_bib58","doi-asserted-by":"crossref","unstructured":"Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seaton TL, McDonnell ND, et al. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos. 1996;24(4):422\u20138.","DOI":"10.1016\/S0090-9556(25)07369-6"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01265-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01265-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01265-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:54:03Z","timestamp":1761807243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923010851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1878747923010851"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01265-0","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluconazole Is Neuroprotective via Interactions with the IGF-1 Receptor","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01265-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}